PET is a functional imaging method that can exploit various aspects of tumor biology to enable greater detection of prostate cancer than can be provided by morphologic imaging alone. Anti-1-amino-3- 18 F-flurocyclobutane-1-carboxylic acid ( 18 F-fluciclovine) is a nonnaturally occurring amino acid PET radiotracer that was recently approved by the U.S. Food and Drug Administration for detection of suspected recurrent prostate cancer. The tumor-imaging features of this radiotracer mirror the upregulation of transmembrane amino acid transport that occurs in prostate cancer because of increased amino acid metabolism for energy and protein synthesis. This continuing medical education article provides an overview on 18 F-fluciclovine PET diagnostic capabilities for primary and metastatic disease, including reviews of published comparisons to conventional imaging and other molecular imaging agents. Additionally, the imaging procedure and image interpretation are detailed, including physiologic and pathologic uptake patterns and pitfalls.
CITATION STYLE
Parent, E. E., & Schuster, D. M. (2018). Update on 18 F-Fluciclovine PET for Prostate Cancer Imaging. Journal of Nuclear Medicine, 59(5), 733–739. https://doi.org/10.2967/jnumed.117.204032
Mendeley helps you to discover research relevant for your work.